Dr Reddy’s Laboratories expects Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks.

“We expect to get the approval in the next few weeks. It is a two-dose vaccine. You take the first dose on Day zero and the second one on day 21. The peak immunity develops somewhere between Day 28 and Day 42. So, it is a two-dose vaccine and we expect it to be available in the next few weeks,” a PTI report quoting Deepak Sapra, CEO, APIs and services at Dr Reddy’s, said.

Sapra disclosed this while speaking at a webinar. He was asked how soon Sputnik would become available and how many doses would be required.

Dr Reddy’s has joined hands with the Russia Direct Investment Fund (RDIF) to bring the Sputnik V vaccine to India and other countries.

Observing that the trials of the vaccine have been conducted in Russia, India, the UAE and others, Sapra said the vaccine demonstrated an efficacy of 91.6 per cent as published in reputed journal Lancet.

The data on trials is at present with the Indian regulator and the company expects to get the green signal in the next few weeks, he added.

“We also conducted trials in India and evaluated the vaccine on the Indian population for both safety as well as for immunogenicity,” he said.

The webinar on “India’s vaccination journey and the second wave of Covid-19” was conducted by the All India Professional Congress (AIPC), Telangana.

During the third quarter ended December 31, 2020, Dr Reddy’s had posted

a consolidated net profit of Rs 27.9 crore compared with a net loss of Rs 538.4 crore during the same period of the previous fiscal.

The company’s total revenue from

operations stood at Rs 4,941.9 crore for the quarter under review, up 12.38 per cent. During the third quarter ended December 31, 2019, the total revenue from operations was at Rs 4,397.1 crore.